logo-loader
Netscientific PLC

NetScientific to focus on extending lifespan as CEO reiterates confidence in portfolio firms

CEO Ian Postlethwaite said the healthcare commercialisation firm had taken measures to reduce its central function costs and was expected to have sufficient cash to operate until the end of 2020

Scientist
The firm ended 2018 with a cash balance of £2.9mln, which had increased to £3mln as of 30 April

NetScientific PLC (LON:NSCI) chief executive Ian Postlethwaite has reiterated the group’s confidence in its remaining portfolio companies, adding that the company would use its cash reserves to focus on extending its lifespan.

The CEO of the healthcare commercialisation firm said in its full-year results that after selling its interests in the Vortex Biosciences and Wanda companies for £150,000 in March, the company had taken measures to reduce its central function costs and was expected to have sufficient cash to operate until the end of 2020.

READ: Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

Two of the company’s portfolio firms, Glycotest and PDS Biotechnology, did not require further funding, while the final firm, ProAxsis, required only a small injection of £100,000 to meet operational requirements which would be repayable in 2019.

For the year ended 31 December 2018, NetScientific reported a loss from continuing operations of £4mln, less than the £4.2mln loss the year before, while revenues rose to £245,000 from £171,000.

The firm also ended the year with a cash balance of £2.9mln, which had increased to £3mln as of 30 April.

In early trading on Wednesday, the shares were down 5.4% at 8.8p.

Quick facts: Netscientific PLC

Price: £0.07

Market: AIM
Market Cap: £5.5 m
Follow

Watch

'Pivotal' moment for NetScientific's Glycotest Inc with $10mln financing

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), spoke to Proactive London's Andrew Scott as their portfolio company Glycotest Inc agreed on terms of a funding round. The US$10mln Series A financing round is with Shanghai Fosun Pharmaceutical, a leading healthcare group...

on 22/10/18

2 min read

;